Brolucizumab Biosimilar, Endotoxin 0.05 EU/mg | C069P.05

Catalog No.	C069P.05
Product Name	Brolucizumab Biosimilar, Endotoxin 0.05 EU/mg | C069P.05
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	VEGF, VEGF-A, vascular endothelial growth factor A
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Human IgG1 kappa.
Source/Host	The anti-human vascular endothelial growth factor A (VEGF-A) monoclonal antibody brolucizumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade brolucizumab biosimilar specifically binds to the human vascular endothelial growth factor A (VEGF-A).
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 0.05 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Brolucizumab Biosimilar, Endotoxin 0.05 EU/mg is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Brolucizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C069P.05: Brolucizumab Biosimilar, Endotoxin 0.05 EU/mg

Recombinant Humanized IgG1 Monoclonal Antibody.

Background

Brolucizumab Biosimilar uses the same protein sequences as the therapeutic antibody brolucizumab.

Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.

Syd Labs also provides the following anti-VEGF antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody
Bevacizumab Biosimilar, L234A L235A P329G (LALAPG) Fc silent mutant
Ramucirumab Biosimilar, research grade, anti-human VEGF / VEGFR2 / VEGFR-2 monoclonal antibody
Ranibizumab Biosimilar, research grade, anti-human VEGF monoclonal antibody

Please remember our product information: Brolucizumab Biosimilar, Endotoxin 0.05 EU/mg: C069P.05 Syd Labs

No more offers for this product!